Spectral Med Inc (EDT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spectral Med Inc (EDT) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-2.67 Million ≈ $-1.93 Million USD) by net assets (CA$-68.66 Million ≈ $-49.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spectral Med Inc - Cash Flow Conversion Efficiency Trend (1992–2024)
This chart illustrates how Spectral Med Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Spectral Med Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Spectral Med Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spectral Med Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MFS Intermediate Income Trust
NYSE:MIN
|
0.046x |
|
James River Group Holdings Ltd
NASDAQ:JRVR
|
0.054x |
|
Stellus Capital Investment
NYSE:SCM
|
-0.054x |
|
Global Standard Technology Limited
KQ:083450
|
0.015x |
|
BROOGE ENERGY DL-0001
F:3SF
|
N/A |
|
JINMAO PROPERTY SERVICES
F:TZ0
|
N/A |
|
Dredging Corporation of India Limited
NSE:DREDGECORP
|
0.151x |
|
Yayla Agro Gida Sanayi ve Ticaret A.S.
IS:YYLGD
|
0.339x |
Annual Cash Flow Conversion Efficiency for Spectral Med Inc (1992–2024)
The table below shows the annual cash flow conversion efficiency of Spectral Med Inc from 1992 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Spectral Med Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-27.55 Million ≈ $-19.93 Million |
CA$-8.82 Million ≈ $-6.38 Million |
0.320x | -50.58% |
| 2023-12-31 | CA$-16.55 Million ≈ $-11.97 Million |
CA$-10.72 Million ≈ $-7.76 Million |
0.648x | -83.29% |
| 2022-12-31 | CA$-2.55 Million ≈ $-1.85 Million |
CA$-9.90 Million ≈ $-7.16 Million |
3.876x | +281.90% |
| 2021-12-31 | CA$4.08 Million ≈ $2.95 Million |
CA$-8.70 Million ≈ $-6.29 Million |
-2.131x | -540.02% |
| 2020-12-31 | CA$-669.00K ≈ $-483.94K |
CA$-324.00K ≈ $-234.38K |
0.484x | +139.98% |
| 2019-12-31 | CA$2.26 Million ≈ $1.63 Million |
CA$-2.74 Million ≈ $-1.98 Million |
-1.212x | -224.12% |
| 2018-12-31 | CA$6.37 Million ≈ $4.61 Million |
CA$-2.38 Million ≈ $-1.72 Million |
-0.374x | +70.28% |
| 2017-12-31 | CA$2.86 Million ≈ $2.07 Million |
CA$-3.60 Million ≈ $-2.60 Million |
-1.258x | +34.17% |
| 2016-12-31 | CA$5.82 Million ≈ $4.21 Million |
CA$-11.12 Million ≈ $-8.05 Million |
-1.911x | -13.63% |
| 2015-12-31 | CA$5.43 Million ≈ $3.93 Million |
CA$-9.14 Million ≈ $-6.61 Million |
-1.682x | -48.20% |
| 2014-12-31 | CA$8.82 Million ≈ $6.38 Million |
CA$-10.01 Million ≈ $-7.24 Million |
-1.135x | +29.68% |
| 2013-12-31 | CA$5.70 Million ≈ $4.12 Million |
CA$-9.19 Million ≈ $-6.65 Million |
-1.614x | -120.87% |
| 2012-12-31 | CA$10.57 Million ≈ $7.65 Million |
CA$-7.72 Million ≈ $-5.59 Million |
-0.731x | -120.57% |
| 2011-12-31 | CA$18.94 Million ≈ $13.70 Million |
CA$-6.27 Million ≈ $-4.54 Million |
-0.331x | -16.50% |
| 2010-12-31 | CA$15.75 Million ≈ $11.39 Million |
CA$-4.48 Million ≈ $-3.24 Million |
-0.284x | +64.97% |
| 2009-12-31 | CA$1.36 Million ≈ $987.42K |
CA$-1.11 Million ≈ $-801.51K |
-0.812x | -528.74% |
| 2008-12-31 | CA$4.05 Million ≈ $2.93 Million |
CA$-523.00K ≈ $-378.33K |
-0.129x | +4.00% |
| 2007-12-31 | CA$5.44 Million ≈ $3.94 Million |
CA$-732.00K ≈ $-529.52K |
-0.134x | +26.00% |
| 2006-12-31 | CA$6.99 Million ≈ $5.06 Million |
CA$-1.27 Million ≈ $-918.70K |
-0.182x | +96.81% |
| 2005-12-31 | CA$738.00K ≈ $533.86K |
CA$-4.21 Million ≈ $-3.04 Million |
-5.703x | -500.54% |
| 2004-12-31 | CA$5.33 Million ≈ $3.85 Million |
CA$-5.06 Million ≈ $-3.66 Million |
-0.950x | -71.08% |
| 2003-12-31 | CA$9.03 Million ≈ $6.53 Million |
CA$-5.01 Million ≈ $-3.63 Million |
-0.555x | +48.99% |
| 2002-12-31 | CA$3.84 Million ≈ $2.78 Million |
CA$-4.18 Million ≈ $-3.02 Million |
-1.088x | -1548.33% |
| 2001-12-31 | CA$8.19 Million ≈ $5.92 Million |
CA$615.00K ≈ $444.88K |
0.075x | +111.47% |
| 2000-12-31 | CA$5.81 Million ≈ $4.20 Million |
CA$-3.80 Million ≈ $-2.75 Million |
-0.655x | -35.38% |
| 1999-12-31 | CA$9.30 Million ≈ $6.73 Million |
CA$-4.50 Million ≈ $-3.26 Million |
-0.484x | +13.98% |
| 1998-12-31 | CA$16.00 Million ≈ $11.57 Million |
CA$-9.00 Million ≈ $-6.51 Million |
-0.563x | -47.94% |
| 1997-12-31 | CA$26.30 Million ≈ $19.03 Million |
CA$-10.00 Million ≈ $-7.23 Million |
-0.380x | -36.39% |
| 1996-12-31 | CA$39.10 Million ≈ $28.28 Million |
CA$-10.90 Million ≈ $-7.88 Million |
-0.279x | +36.15% |
| 1995-12-31 | CA$28.40 Million ≈ $20.54 Million |
CA$-12.40 Million ≈ $-8.97 Million |
-0.437x | -128.79% |
| 1994-12-31 | CA$39.30 Million ≈ $28.43 Million |
CA$-7.50 Million ≈ $-5.43 Million |
-0.191x | +5.18% |
| 1993-12-31 | CA$15.90 Million ≈ $11.50 Million |
CA$-3.20 Million ≈ $-2.31 Million |
-0.201x | +66.75% |
| 1992-12-31 | CA$3.80 Million ≈ $2.75 Million |
CA$-2.30 Million ≈ $-1.66 Million |
-0.605x | -- |
About Spectral Med Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device … Read more